The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer.
- Author:
Ik Chan SONG
1
;
Hyo Jin LEE
;
Young Jun YANG
;
Yoon Seok CHOI
;
Hye Won RYU
;
Myung Won LEE
;
Ji Young MOON
;
Deog Yeon JO
;
Samyong KIM
;
Hwan Jung YUN
Author Information
- Publication Type:Original Article
- Keywords: Non-small-cell lung carcinoma; Third-line treatment; Drug therapy
- MeSH: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung*; Chungcheongnam-do; Disease-Free Survival; Drug Therapy*; Humans; Neutropenia
- From:Cancer Research and Treatment 2015;47(4):638-644
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: There is no regimen that is strongly recommended for more than second-line treatment. We investigated the efficacy and safety of platinum/vinorelbine as more than second-line treatment. MATERIALS AND METHODS: We selected patients with advanced non-small cell lung cancer (NSCLC) who received treatment with platinum/vinorelbine at Chungnam National University Hospital from August 2001 to December 2013. The primary end point was the response rate, and secondary end points were progression-free survival (PFS), overall survival (OS), and toxicity. RESULTS: Thirty-five patients were enrolled. Response rate was 22.9% (complete response, 0 patients [0%]; partial response, eight patients [22.9%]; stable disease, 10 patients [28.6%]; progressive disease, 14 patients [40.0%]). A significantly higher response rate was observed for patients who had responded to previous chemotherapy than for those who did not (34.8% [8/23] vs. 0% [0/12], p=0.020). The median PFS was 4 months (range, 1 to 21 months). Patients with adenocarcinoma and non-smokers had a significantly longer PFS than patients with non-adenocarcinoma and smokers (5 months vs. 2 months, p=0.007; 4.5 months vs. 2 months, p=0.046, respectively). The median OS was 10 months (range, 1 to 41 months). Patients with good performance status and non-smokers had a significantly longer OS than patients with poor performance status and smokers (14 months vs. 4 months, p=0.02; 18.5 months vs. 6 months, p=0.049, respectively). The main serious adverse event (grade 3 or 4) was neutropenia (15 events, 13.3%) in a total of 113 cycles. CONCLUSION: Platinum/vinorelbine was effective as more than second-line chemotherapy, and the toxicity was tolerable, in patients with advanced NSCLC.
